11.43 USD
+0.03 (+0.26%)
11.43 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to XRAY. XRAY was compared to 186 industry peers in the Health Care Equipment & Supplies industry. XRAY has a medium profitability rating, but doesn't score so well on its financial health evaluation. XRAY is valued quite cheap, but it does not seem to be growing. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year XRAY was profitable.
XRAY had a positive operating cash flow in the past year.
In the past 5 years XRAY reported 4 times negative net income.
In the past 5 years XRAY always reported a positive cash flow from operatings.
1.2 Ratios
XRAY has a Return On Assets (-15.60%) which is comparable to the rest of the industry.
With a Return On Equity value of -59.68%, XRAY perfoms like the industry average, outperforming 47.85% of the companies in the same industry.
The Return On Invested Capital of XRAY (5.04%) is better than 76.34% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for XRAY is below the industry average of 8.84%.
The 3 year average ROIC (4.11%) for XRAY is below the current ROIC(5.04%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
XRAY has a Operating Margin of 7.48%. This is in the better half of the industry: XRAY outperforms 74.19% of its industry peers.
XRAY's Operating Margin has declined in the last couple of years.
XRAY has a Gross Margin (51.10%) which is in line with its industry peers.
In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
XRAY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
XRAY has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, XRAY has less shares outstanding
The debt/assets ratio for XRAY is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.93, we must say that XRAY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 0.93, XRAY perfoms like the industry average, outperforming 52.15% of the companies in the same industry.
The Debt to FCF ratio of XRAY is 29.94, which is on the high side as it means it would take XRAY, 29.94 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 29.94, XRAY is doing good in the industry, outperforming 68.82% of the companies in the same industry.
XRAY has a Debt/Equity ratio of 1.36. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.36, XRAY is not doing good in the industry: 77.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.93 |
ROIC/WACC0.81
WACC6.2%
2.3 Liquidity
A Current Ratio of 1.47 indicates that XRAY should not have too much problems paying its short term obligations.
XRAY's Current ratio of 1.47 is on the low side compared to the rest of the industry. XRAY is outperformed by 74.19% of its industry peers.
XRAY has a Quick Ratio of 1.47. This is a bad value and indicates that XRAY is not financially healthy enough and could expect problems in meeting its short term obligations.
XRAY has a worse Quick ratio (0.99) than 74.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
XRAY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.59%.
Measured over the past years, XRAY shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.38% on average per year.
XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -7.08%.
XRAY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.17% yearly.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
Based on estimates for the next years, XRAY will show a small growth in Earnings Per Share. The EPS will grow by 7.40% on average per year.
The Revenue is expected to grow by 1.34% on average over the next years.
EPS Next Y-2.07%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
EPS Next 5Y7.4%
Revenue Next Year-4.33%
Revenue Next 2Y-1.82%
Revenue Next 3Y-0.42%
Revenue Next 5Y1.34%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 7.23, the valuation of XRAY can be described as very cheap.
Based on the Price/Earnings ratio, XRAY is valued cheaper than 97.31% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. XRAY is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 7.15, the valuation of XRAY can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 98.92% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.13, XRAY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.23 | ||
| Fwd PE | 7.15 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.24% of the companies listed in the same industry.
XRAY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. XRAY is cheaper than 80.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.51 | ||
| EV/EBITDA | 6.98 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
5. Dividend
5.1 Amount
XRAY has a Yearly Dividend Yield of 4.91%, which is a nice return.
XRAY's Dividend Yield is rather good when compared to the industry average which is at 0.20. XRAY pays more dividend than 99.46% of the companies in the same industry.
XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
5.2 History
On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
XRAY's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
11.43
+0.03 (+0.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners107.05%
Inst Owner Change9.76%
Ins Owners0.29%
Ins Owner Change-3.01%
Market Cap2.28B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts69.52
Price Target12.79 (11.9%)
Short Float %6.14%
Short Ratio3.35
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)-1.53%
PT rev (3m)-25.35%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-42.56%
EPS NY rev (1m)-14.63%
EPS NY rev (3m)-15.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.3%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.23 | ||
| Fwd PE | 7.15 | ||
| P/S | 0.63 | ||
| P/FCF | 28.51 | ||
| P/OCF | 10.32 | ||
| P/B | 1.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.98 |
EPS(TTM)1.58
EY13.82%
EPS(NY)1.6
Fwd EY13.99%
FCF(TTM)0.4
FCFY3.51%
OCF(TTM)1.11
OCFY9.69%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.93 |
F-Score4
WACC6.2%
ROIC/WACC0.81
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y-2.07%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.33%
Revenue Next 2Y-1.82%
Revenue Next 3Y-0.42%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year42.44%
EBIT Next 3Y14.41%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
What is the ChartMill fundamental rating of DENTSPLY SIRONA INC (XRAY) stock?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
What is the valuation status for XRAY stock?
ChartMill assigns a valuation rating of 7 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for XRAY stock?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 7.23 and the Price/Book (PB) ratio is 1.54.
Can you provide the dividend sustainability for XRAY stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.